In software ecosystems, a single platform decision can rapidly reshape the environment for developers. Access to tools, distribution channels and global markets can change almost overnight. A policy adjustment by a platform owner can determine which products can be built, distributed or updated in a particular market.
Life sciences operates very differently. Instead of platforms, the system is shaped by regulatory frameworks, clinical evidence standards and national healthcare systems. Change tends to be slower, procedural and often less visible to the outside world. But the underlying dynamic may be comparable: international collaboration depends on multiple systems continuing to align in workable ways.
Across the UK and Europe, regulatory expectations are evolving through frameworks such as the EU Medical Device Regulation (MDR), the UK’s emerging post-Brexit regulatory regime and the forthcoming EU AI Act. These frameworks create dense but relatively transparent expectations around safety, clinical evidence and data governance. For companies developing medical devices, diagnostics or AI-enabled health technologies, these regimes increasingly define what evidence must look like before innovation can reach patients.
China’s regulatory landscape is also evolving rapidly. Reforms led by the National Medical Products Administration (NMPA), alongside new approaches to clinical data, real-world evidence and cross-border data governance, are reshaping how Chinese biotechs and healthcare innovators develop products and engage international markets. China has accelerated review pathways in several therapeutic areas and has increasingly encouraged domestic innovation in areas such as cell therapies and digital health. At the same time, evolving rules around data governance and cross-border data flows introduce additional complexity for international collaborations involving clinical trials or digital health platforms.
The result is not necessarily a single market closing, but something more subtle: a gradual divergence of regulatory systems.
For organisations working across the UK, EU and China, this divergence presents practical challenges that extend beyond policy headlines. Clinical development strategies increasingly need to consider whether trial designs will satisfy multiple regulators simultaneously. Data governance frameworks must account for different expectations around patient privacy, data localisation and cross-border transfer. AI-enabled medical technologies face emerging regulatory pathways that are still being defined in parallel across several jurisdictions.
In practice, many organisations operating internationally are already navigating levels of regulatory and governance complexity that existing institutional frameworks were not originally designed to manage. While regulators continue to refine policies and international cooperation mechanisms, companies, research institutions and healthcare innovators often find themselves addressing these challenges in real time as they design clinical programmes, partnerships and data strategies.
Against this backdrop, several practical questions are beginning to surface more frequently in boardrooms and leadership discussions.
First, can scientific programmes remain coherent across multiple regulatory environments at once? A clinical trial or digital health platform designed to satisfy one regulatory regime may not automatically meet the evidentiary expectations of another. Ensuring scientific integrity while adapting to different regulatory logics increasingly requires careful planning at the earliest stages of product development.
Second, do cross-border partnerships include governance mechanisms that allow collaboration to pause, adapt or re-sequence if regulatory or policy conditions change? International research and commercial partnerships often span many years. Building in the ability to adjust programme design without undermining trust or long-term scientific goals is becoming an important feature of resilient collaboration.
Third, are organisations developing teams capable of working across regulatory and institutional cultures? Scientific expertise remains essential, but it is often the ability to interpret and translate regulatory expectations between systems — such as the MHRA, EMA and NMPA — that determines whether collaboration proceeds smoothly.
These questions reflect a broader shift in the nature of international collaboration. In previous decades, global scientific partnerships often assumed a relatively stable regulatory environment. Today, the environment is more dynamic. National innovation strategies, data governance frameworks and regulatory expectations are evolving simultaneously across several regions.
Unity’s situation in the gaming sector illustrates how quickly ecosystems can change when commercial pressures, governance decisions and geopolitics intersect. In life sciences the pace of change may be slower, but the long-term implications can be just as significant.
Clinical development, licensing strategies, digital health innovation and AI-assisted research all depend on the ability to translate not only language, but also standards of evidence, regulatory expectations and institutional practices.
As regulatory systems gradually evolve in different directions, the challenge for organisations may be less about choosing between markets and more about designing collaboration that can operate across several regulatory logics at once.
Through EFEC’s work supporting responsible UK–China life sciences collaboration, we increasingly see organisations grappling with these questions in practical ways. The ability to navigate complexity thoughtfully — combining scientific excellence with careful governance design — is becoming an increasingly important capability for international life sciences partnerships.
Unity’s decision may belong to another sector, but it raises a useful question for life sciences leaders: as systems gradually drift apart, are your science, partnerships and teams designed to keep moving between them?
Disclaimer
The views expressed are the author’s own reflections and do not represent the positions of any partner organisations.
Image: Professionals discussing collaboration in a Cambridge research environment, reflecting the growing need to navigate different regulatory systems across the UK, EU and China.
